BioSpace News Archive

BioImpact Capital, an affiliate of MPM Capital, announced that Orna Therapeutics, a portfolio company it created, incubated, and funded, has agreed to a landmark collaboration with one of the world’s leading biopharmaceutical companies.

Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Chief Executive Officer Dr. Megan Baldwin will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place virtually on August 17, 2022.

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, announced 36-month post-surgery follow-up results of the OMNI® Surgical System.

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022.

Intellipharmaceutics International Inc announced that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc., by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory of Health Canada.

Aytu BioPharma, Inc. today announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,273,148 (the “‘148 patent”), for AR101/Enzastaurin.

Abiomed (Nasdaq: ABMD) announces the results of the Restore EF study demonstrate Impella-supported high-risk percutaneous coronary intervention (PCI) leads to significant improvements in left ventricular ejection fraction (LVEF), angina symptoms and heart failure symptoms at follow-up.

enVVeno Medical Corporation today announced the appointment of Kevin Belteau as Vice President of Clinical Operations.

SELLAS Life Sciences Group, Inc. today announced the election of Katherine Bach Kalin to its Board of Directors.

Processa Pharmaceuticals, Inc. announced today the appointment of Khoso Baluch and James Neal to its Board of Directors.